The burden of heart failure (HF), developing after myocardial infarction MI, still represents a
major issue in clinical practice. Failure of appropriate resolution of inflammation during post …

Chronic graft rejection remains a significant barrier to solid organ transplantation as a
treatment for end-organ failure. Patients receiving organ transplants typically require …

Mechanistic target of rapamycin (mTOR) forms two distinct complexes, mTOR complex 1
(mTORC1) and mTORC2. Here we investigated the antitumor effect of dual mTORC1/2 …

Loss of function of tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) leads to the activation
of mammalian target of rapamycin complex 1 (mTORC1). Hyperactivated mTORC1 plays a …

Dendritic cells (DCs) are unique immune cells that can link innate and adaptive immune
responses and Immunometabolism greatly impacts their phenotype. Rapamycin is a …

AKI remains highly prevalent, yet no optimal therapy is available to prevent it or promote
recovery after initial insult. Experimental studies have demonstrated that both innate and …

Background Skin wounds in diabetic patients hardly recover. Accumulating evidence has
shown that mammalian target of rapamycin (mTOR) pathway and myeloid-derived …

Myeloid-derived suppressor cells (MDSC) are induced during active TB disease to restore
immune homeostasis but instead exacerbate disease outcome due to chronic inflammation …

Background Myeloid-derived suppressor cells (MDSCs) can prevent allograft rejection and
induce immune tolerance in transplantation models. Previous studies have demonstrated …

Background Organ transplant recipients show a high incidence for the formation of
cutaneous squamous cell carcinoma (cSCC), while sirolimus appears to reduce the risk …